Role of Aldehyde Dehydrogenase 2 in 1-Methy-4-Phenylpyridinium Ion-Induced Aldehyde Stress and Cytotoxicity in PC12 Cells

Neurochemical Research

Volumn 39, Issue 9, 2014, Pages 1767-1775

  Chen, Ai Hua ^a   Zhang, Ping ^a   Yin, Wei Lan ^a   Wang, Li ^a   Zou, Wei ^a   Tang, Xiao Qing ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

1 Methy 4 Phenylpyridinium Ion; 4 Hydroxynonenal; Aldehyde dehydrogenase 2; Aldehyde stress; Malonaldehyde; Neurotoxicity

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; ALDEHYDE; ALDEHYDE DEHYDROGENASE; ALDH2 PROTEIN, RAT; DAIDZIN; ENZYME INHIBITOR; ISOFLAVONE DERIVATIVE; MITOCHONDRIAL PROTEIN;

ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; OXIDATIVE STRESS; PC12 CELL LINE; RAT;

1-METHYL-4-PHENYLPYRIDINIUM; ALDEHYDE DEHYDROGENASE; ALDEHYDES; ANIMALS; ENZYME INHIBITORS; ISOFLAVONES; MITOCHONDRIAL PROTEINS; OXIDATIVE STRESS; PC12 CELLS; RATS;

EID: 84939894818     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-014-1376-1     Document Type: Article

References (51)

1. Dawson TM, Dawson VL (2002) Neuroprotective and neurorestorative strategies for Parkinson’s disease. Nat Neurosci 5(Suppl):1058–1061
2. Wood PL, Khan MA, Kulow SR, Mahmood SA, Moskal JR (2006) Neurotoxicity of reactive aldehydes: the concept of “aldehyde load” as demonstrated by neuroprotection with hydroxylamines. Brain Res 1095:190–199
3. Wood PL, Khan MA, Moskal JR (2007) The concept of “aldehyde load” in neurodegenerative mechanisms: cytotoxicity of the polyamine degradation products hydrogen peroxide, acrolein, 3-aminopropanal, 3-acetamidopropanal and 4-aminobutanal in a retinal ganglion cell line. Brain Res 1145:150–156
4. Wood PL (2006) Neurodegeneration and aldehyde load: from concept to therapeutics. J Psychiatry Neurosci 31:296–297
5. Ellis EM (2007) Reactive carbonyls and oxidative stress: potential for therapeutic intervention. Pharmacol Ther 115:13–24
6. Uchida K (2000) Role of reactive aldehyde in cardiovascular diseases. Free Radic Biol Med 28:1685–1696
7. Aldini G, Dalle-Donne I, Facino RM, Milzani A, Carini M (2007) Intervention strategies to inhibit protein carbonylation by lipoxidation-derived reactive carbonyls. Med Res Rev 27:817–868
8. Jinsmaa Y, Florang VR, Rees JN, Mexas LM, Eckert LL et al (2011) Dopamine-derived biological reactive intermediates and protein modifications: implications for Parkinson’s disease. Chem Biol Interact 192:118–121
9. Qin Z, Hu D, Han S, Reaney SH, Di Monte DA et al (2007) Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. J Biol Chem 282:5862–5870
10. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER et al (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA 93:2696–2701
11. Selley ML (1998) (E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson’s disease. Free Radic Biol Med 25:169–174
12. Farooqui T, Farooqui AA (2011) Lipid-mediated oxidative stress and inflammation in the pathogenesis of Parkinson’s disease. Parkinsons Dis 2011:247467
13. Xiang W, Schlachetzki JC, Helling S, Bussmann JC, Berlinghof M et al (2013) Oxidative stress-induced posttranslational modifications of alpha-synuclein: specific modification of alpha-synuclein by 4-hydroxy-2-nonenal increases dopaminergic toxicity. Mol Cell Neurosci 54:71–83
14. Przedborski S, Tieu K, Perier C, Vila M (2004) MPTP as a mitochondrial neurotoxic model of Parkinson’s disease. J Bioenerg Biomembr 36:375–379
15. Abou-Sleiman PM, Muqit MM, Wood NW (2006) Expanding insights of mitochondrial dysfunction in Parkinson’s disease. Nat Rev Neurosci 7:207–219
16. Zhu Q, Wang J, Zhang Y, Sun S (2012) Mechanisms of MPP(+)-induced PC12 cell apoptosis via reactive oxygen species. J Huazhong Univ Sci Technolog Med Sci 32:861–866
17. Zawada WM, Banninger GP, Thornton J, Marriott B, Cantu D et al (2011) Generation of reactive oxygen species in 1-methyl-4-phenylpyridinium (MPP+) treated dopaminergic neurons occurs as an NADPH oxidase-dependent two-wave cascade. J Neuroinflammation 8:129
18. Tang XQ, Fan LL, Li YJ, Shen XT, Zhuan YY et al (2011) Inhibition of hydrogen sulfide generation contributes to 1-methy-4-phenylpyridinium ion-induced neurotoxicity. Neurotox Res 19:403–411
19. Qian JJ, Cheng YB, Yang YP, Mao CJ, Qin ZH et al (2008) Differential effects of overexpression of wild-type and mutant human alpha-synuclein on MPP+ -induced neurotoxicity in PC12 cells. Neurosci Lett 435:142–146
20. Wu Y, Shang Y, Sun S, Liang H, Liu R (2007) Erythropoietin prevents PC12 cells from 1-methyl-4-phenylpyridinium ion-induced apoptosis via the Akt/GSK-3beta/caspase-3 mediated signaling pathway. Apoptosis 12:1365–1375
21. Yamamoto N, Sawada H, Izumi Y, Kume T, Katsuki H et al (2007) Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease. J Biol Chem 282:4364–4372
22. Tang XQ, Li YJ, Zhao J, Shen XT, Yang CT et al (2010) Neuroprotective effect of asymmetric dimethylarginine against 1-methyl-4-phenylpyridinium ion-induced damage in PC12 cells. Clin Exp Pharmacol Physiol 37:530–535
23. Siddiqui MA, Kumar V, Kashyap MP, Agarwal M, Singh AK et al (2012) Short-term exposure of 4-hydroxynonenal induces mitochondria-mediated apoptosis in PC12 cells. Hum Exp Toxicol 31:336–345
24. Chen CH, Budas GR, Churchill EN, Disatnik MH, Hurley TD et al (2008) Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 321:1493–1495
25. Hyun DH, Lee MH, Halliwell B, Jenner P (2002) Proteasomal dysfunction induced by 4-hydroxy-2,3-trans-nonenal, an end-product of lipid peroxidation: a mechanism contributing to neurodegeneration? J Neurochem 83:360–370
26. Lee WC, Wong HY, Chai YY, Shi CW, Amino N et al (2012) Lipid peroxidation dysregulation in ischemic stroke: plasma 4-HNE as a potential biomarker? Biochem Biophys Res Commun 425:842–847
27. Ohsawa I, Nishimaki K, Yasuda C, Kamino K, Ohta S (2003) Deficiency in a mitochondrial aldehyde dehydrogenase increases vulnerability to oxidative stress in PC12 cells. J Neurochem 84:1110–1117
28. Keung WM (2001) Biogenic aldehyde(s) derived from the action of monoamine oxidase may mediate the antidipsotropic effect of daidzin. Chem Biol Interact 130–132:919–930
29. Keung WM, Vallee BL (1993) Daidzin: a potent, selective inhibitor of human mitochondrial aldehyde dehydrogenase. Proc Natl Acad Sci USA 90:1247–1251
30. Sai T, Uchida K, Nakayama H (2013) Involvement of monoamine oxidase-B in the acute neurotoxicity of MPTP in embryonic and newborn mice. Exp Toxicol Pathol 65:365–373
31. Hsieh YC, Mounsey RB, Teismann P (2011) MPP(+)-induced toxicity in the presence of dopamine is mediated by COX-2 through oxidative stress. Naunyn Schmiedebergs Arch Pharmacol 384:157–167
32. Jin BK, Shin DY, Jeong MY, Gwag MR, Baik HW et al (1998) Melatonin protects nigral dopaminergic neurons from 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity in rats. Neurosci Lett 245:61–64
33. Jang YJ, Kim J, Shim J, Byun S, Oak MH et al (2011) Kaempferol attenuates 4-hydroxynonenal-induced apoptosis in PC12 cells by directly inhibiting NADPH oxidase. J Pharmacol Exp Ther 337:747–754
34. Mattammal MB, Haring JH, Chung HD, Raghu G, Strong R (1995) An endogenous dopaminergic neurotoxin: implication for Parkinson’s disease. Neurodegeneration 4:271–281
35. Burke WJ, Li SW, Williams EA, Nonneman R, Zahm DS (2003) 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson’s disease pathogenesis. Brain Res 989:205–213
36. Rojas P, Serrano-Garcia N, Medina-Campos ON, Pedraza-Chaverri J, Maldonado PD et al (2011) S-Allylcysteine, a garlic compound, protects against oxidative stress in 1-methyl-4-phenylpyridinium-induced parkinsonism in mice. J Nutr Biochem 22:937–944
37. Chiueh CC, Andoh T, Lai AR, Lai E, Krishna G (2000) Neuroprotective strategies in Parkinson’s disease: protection against progressive nigral damage induced by free radicals. Neurotox Res 2:293–310
38. Chan KC, Mong MC, Yin MC (2009) Antioxidative and anti-inflammatory neuroprotective effects of astaxanthin and canthaxanthin in nerve growth factor differentiated PC12 cells. J Food Sci 74:H225–H231
39. Cheng B, Yang X, Chen C, Cheng D, Xu X et al (2010) D-beta-hydroxybutyrate prevents MPP+ -induced neurotoxicity in PC12 cells. Neurochem Res 35:444–451
40. Conklin D, Prough R, Bhatanagar A (2007) Aldehyde metabolism in the cardiovascular system. Mol BioSyst 3:136–150
41. Vasiliou V, Pappa A, Estey T (2004) Role of human aldehyde dehydrogenases in endobiotic and xenobiotic metabolism. Drug Metab Rev 36:279–299
42. Vasiliou V, Nebert DW (2005) Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family. Hum Genomics 2:138–143
43. Yoval-Sanchez B, Rodriguez-Zavala JS (2012) Differences in susceptibility to inactivation of human aldehyde dehydrogenases by lipid peroxidation byproducts. Chem Res Toxicol 25:722–729
44. Solito R, Corti F, Chen CH, Mochly-Rosen D, Giachetti A et al (2013) Mitochondrial aldehyde dehydrogenase-2 activation prevents beta-amyloid-induced endothelial cell dysfunction and restores angiogenesis. J Cell Sci 126:1952–1961
45. Ohta S, Ohsawa I, Kamino K, Ando F, Shimokata H (2004) Mitochondrial ALDH2 deficiency as an oxidative stress. Ann N Y Acad Sci 1011:36–44
46. Ma H, Guo R, Yu L, Zhang Y, Ren J (2011) Aldehyde dehydrogenase 2 (ALDH2) rescues myocardial ischaemia/reperfusion injury: role of autophagy paradox and toxic aldehyde. Eur Heart J 32:1025–1038
47. He L, Liu B, Dai Z, Zhang HF, Zhang YS et al (2012) Alpha lipoic acid protects heart against myocardial ischemia-reperfusion injury through a mechanism involving aldehyde dehydrogenase 2 activation. Eur J Pharmacol 678:32–38
48. Kong D, Kotraiah V (2012) Modulation of aldehyde dehydrogenase activity affects (±)-4-hydroxy-2E-nonenal (HNE) toxicity and HNE-protein adduct levels in PC12 cells. J Mol Neurosci 47:595–603
49. Wey MC, Fernandez E, Martinez PA, Sullivan P, Goldstein DS et al (2012) Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson’s disease. PLoS ONE 7:e31522
50. Fitzmaurice AG, Rhodes SL, Lulla A, Murphy NP, Lam HA et al (2013) Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease. Proc Natl Acad Sci USA 110:636–641
51. Klaidman LK, Adams JD Jr, Leung AC, Kim SS, Cadenas E (1993) Redox cycling of MPP+: evidence for a new mechanism involving hydride transfer with xanthine oxidase, aldehyde dehydrogenase, and lipoamide dehydrogenase. Free Radic Biol Med 15:169–179